Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575288 | 0.93 | PTGES (0.44) | PTGESPPARGTHRBSMN1; SMN2TP53 | |
| SCHEMBL4923368 | 0.91 | PPARG (0.45) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL27698393 | 0.89 | PPARG (0.40) | PTGESPPARGPPARASMN1; SMN2ALOX5 | |
| SCHEMBL4700259 | 0.83 | BTK (0.41) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL3007903 | 0.83 | PTGES (0.43) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL4021254 | 0.82 | PTGES (0.59) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL4698398 | 0.81 | PTGES (0.55) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL3001790 | 0.80 | KDM4E (0.40) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL3007687 | 0.80 | PPARG (0.45) | PTGESPPARGPPARATHRBSMN1; SMN2 | |
| SCHEMBL4918614 | 0.80 | PPARG (0.47) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | PTGES 4/4885PPARG 753/4885PPARA 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.